The Swedish biotech leads the first subjects in the new ATR-258 study and believes that the next breakthrough in obesity will be about muscle protection.
Swedish Stage Clinical Biotechnology Atrogy The first subjects in a new human trial of ATR-258, the lead oral drug candidate, marked a new milestone for a biotech company trying to answer one of the most pressing questions in metabolic medicine: Can you help people lose fat without sacrificing muscle?
The current epidemic of obesity and drugs has changed the conversation about weight loss. However, as powerful new treatments move into the mainstream, there is also a more complex reality: not all weight loss is created equal. When the number on the scale goes down, some of the things missing can be muscle, and for older adults, that means less strength, less stamina, and a harder road to healthy aging.
Atrogi wants to put the ATR-258 on the other side of this problem. Stockholm Biotechnology announced that the first participants have now been assigned to an 8-week interventional investigator study evaluating the effects of ATR-258 on the muscle of overweight male volunteers.1). The drug is designed as an oral therapy that aims to mimic some of the metabolic and muscular effects of exercise.
If that sounds ambitious, it is, but it also sits on one of the most compelling investment propositions in longevity. Body composition becomes more important than just body weight.
Atrogi is set to introduce a pill that aims to do more than just reduce the pound sterling. The company describes ATR-258 as a first-in-class oral treatment that has the potential to reduce fat, increase muscle, and improve metabolism.
Instead of simply telling the body to eat less or store less, ATR-258 is designed to stimulate muscle tissue to perform more during exercise, burn fuel more efficiently, and preserve the lean tissue that makes us stronger.
Instead of just looking at how people lose weight, researchers are trying to find out if ATR-258 can affect the quality of weight loss. In other words, can it help the body retain the “good stuff” while shedding excess?
Muscle mass is one of the best predictors of aging in humans. It supports mobility, glucose control, balance, recovery and independence. Losing fat can improve health. Losing muscle at one time can quietly destroy it.
Why does Atrogi think this approach is different? The study, led by Associate Professor Morten Hostrup from the University of Copenhagen, will examine how ATR-258 affects human skeletal muscle through daily oral dosing over eight weeks.
“This trial allows us to critically interrogate targeted downstream effector signaling associated with β2-adrenergic receptors in human skeletal muscle using a highly selective next-generation modulator,” said Hostrup.
The team wants to see if this more targeted drug can precisely activate muscle-building and metabolic pathways, rather than blowing up the entire system and causing side effects.
Hostrup added that the goal is to understand how this approach can be used “to preserve or even increase muscle function under various conditions of muscle wasting, such as immobilization, aging, and weight loss.”
This is the list where the story expands. This is not just an obesity drug treatise. It’s also a treatise on muscle health and opens the door to a broader longevity conversation around frailty, sarcopenia, and the slow erosion of physical function that often defines later life than any single disease.
Atrogi says that the proceedings on the impulse from a June 2025 Cell publication validation of its platform, as well as phase 1 human data in 69 subjects, showed that ATR-258 was safe and well tolerated in healthy volunteers and patients with type 2 diabetes.
Professor Tore Bengtsson, founder and chief scientific officer of Atrogi, expressed excitement about Hostrup’s commitment to researching the effects of the ATR-258 signal missile. He noted that Hostrup is a widely recognized expert in the field and that this new study builds on findings published in Cell in June 2025.
Bengtsson further noted that Hostrup’s decision to sponsor the research confirms the strength of Atrogi’s science and technology, adding that the company expects to share the results later this year.
Paul Little, Atrogi’s chief executive, called the first dose “an important milestone” and said the muscle physiology data would help develop the drug in “metabolic and muscle conditions.”
Investors should note the following caveats. This is early-stage biotechnology, and “exercise mimics” have long been one of the most exciting but problematic ideas in the field. A promising mechanism is one that lacks clinical success. A carefully designed human study does not guarantee that patients will achieve sustained and meaningful benefit.
However, Atrogi’s timing seems reasonable. The obesity market is maturing. The first wave rewarded treatments that helped people lose weight quickly. The next wave could reward treatments that make people lose weight better—preserving muscle, improving function, and metabolic health over decades, not just quarters.
This is where it becomes a story of longevity. The most exciting companies in this space are asking a more challenging and rewarding question: how do we help people stay strong enough to enjoy the years they already have? At the moment, Atrogi has taken a small but meaningful step to answer this.
